Feedback
Settings

Settings

Goto Application

1. WO2001055362 - HYBRID ADENO-RETROVIRAL VECTOR FOR THE TRANSFECTION OF CELLS

PermaLink
Publication Number WO/2001/055362
Publication Date 02.08.2001
International Application No. PCT/US2001/003026
International Filing Date 30.01.2001
Chapter 2 Demand Filed 27.08.2001
IPC
A61K 48/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 15/86 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
C12N 15/861 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
861Adenoviral vectors
C12N 15/867 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
867Retroviral vectors
CPC
A61K 35/13
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
13Tumour cells, irrespective of tissue of origin
A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 43/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
C12N 15/86
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
C12N 2710/10343
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2710dsDNA Viruses
00011dsDNA Viruses
10011Adenoviridae
10311Mastadenovirus, e.g. human or simian adenoviruses
10341Use of virus, viral particle or viral elements as a vector
10343viral genome or elements thereof as genetic vector
C12N 2710/10344
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2710dsDNA Viruses
00011dsDNA Viruses
10011Adenoviridae
10311Mastadenovirus, e.g. human or simian adenoviruses
10341Use of virus, viral particle or viral elements as a vector
10344Chimeric viral vector comprising heterologous viral elements for production of another viral vector
Applicants
  • THE GOVERNEMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTEMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH [US]/[US] (AllExceptUS)
  • ZHENG, Changyu [CN]/[US] (UsOnly)
  • O'CONNELL, Brian [US]/[IE] (UsOnly)
  • BAUM, Bruce, J. [US]/[US] (UsOnly)
Inventors
  • ZHENG, Changyu
  • O'CONNELL, Brian
  • BAUM, Bruce, J.
Agents
  • NOONAN, William, D.
Priority Data
60/179,32731.01.2000US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) HYBRID ADENO-RETROVIRAL VECTOR FOR THE TRANSFECTION OF CELLS
(FR) VECTEUR ADENO-RETROVIRAL HYBRIDE POUR LA TRANSFECTION DE CELLULES
front page image
Abstract
(EN) An adenovirus, including adenoviral capsid proteins, and a replication-defective adenoviral vector that includes a 5" retroviral LTR nucleic acid sequence, a 3" retroviral LTR nucleic acid sequence, a nucleic acid sequence encoding a portion of a retroviral envelope protein adjacent to either the 5" LTR or the 3" LTR nucleic acid sequence, a retroviral packaging sequence and a nucleic acid sequence encoding a transgene located between the 5" LTR and the 3" LTR is provided. Host cells infected with this adenovirus are also provided. An adenoviral vector is provided that includes an adenoviral polynucleotide sequence comprising a nucleic acid encoding a transgene, a retroviral packaging signal, a 5" and a 3" retroviral LTR, and a portion of a retroviral envelope polypeptide, wherein the adenoviral polynucleotide sequence does not encode one or more of E1, E3 or E4. A method for transforming a cell is also provided using a virus or a vector of the invention, as is a method for introducing a transgene into a cell that is not able to produce viral particles with a single viral vector. A method is also provided for preventing or treating disorder in a subject using the adenoviral vectors of the invention. A pharmaceutical composition is also provided that includes an adenoviral vector of the invention and a pharmaceutically acceptable carrier.
(FR) L"invention concerne un adénovirus, y compris des protéines de capside adénovirale, et un vecteur adénoviral à réplication défectueuse qui comprend une séquence d"acides nucléiques rétrovirale de longue répétition terminale 5", une séquence d"acides nucléiques de longue répétition terminale 3", une séquence d"acides nucléiques codant pour une partie de protéine d"enveloppe rétrovirale adjacente à la séquence d"acides nucléiques de longue répétition terminale 5" ou de longue répétition terminale 3", une séquence d"encapsidation rétrovirale et une séquence d"acides nucléiques codant pour un transgène situé entre la longue répétition terminale 5" et la longue répétition terminale 3". L"invention concerne aussi des cellules hôtes infectées à l"aide de cet adénovirus ; et un vecteur adénoviral contenant une séquence polynucléotidique adénovirale qui comprend un acide nucléique codant pour un transgène, un signal d"encapsidation rétrovirale, une longue répétition terminale 5" et une longue répétition terminale 3" rétrovirales, et une partie d"un polypeptide d"enveloppe rétrovirale, cette séquence polynucléotidique adénovirale ne codant pas pour un ou plusieurs des éléments E1, E3 et E4. L"invention concerne aussi un procédé permettant de transformer une cellule à l"aide d"un virus ou d"un vecteur de l"invention, et un procédé permettant d"introduire dans une cellule, au moyen d"un vecteur viral unique, un transgène incapable de produire des particules virales. L"invention concerne en outre une méthode permettant de prévenir ou de traiter une affection chez un sujet à l"aide des vecteurs adénoviraux de l"invention. Une composition pharmaceutique comprenant un vecteur adénoviral de l"invention et un excipient pharmaceutiquement acceptable.
Related patent documents
AU2001233132
US20040115788
US20060035371
US20090258935
Latest bibliographic data on file with the International Bureau
# -